Living Cell Technologies finalises technology acquisition
Thursday, 19 May, 2005
Auckland-based cell therapy company Living Cell Technologies (ASX:LCT) will hold a general meeting next week to formally seal a deal under which it has acquired technology and IP worth US$90 million from with US cell-therapy company Theracyte.
In March, LCT announced it had acquired the rights and IP for a Theracyte device consisting of small, flat metal 'pillows' that can be implanted beneath the skin to deliver sustained doses of drugs, or growth factors from encapsulated cells, to treat disease.
LCT's UK-based chairman, Mr Mick Yates, will update shareholders at the meeting, to be held at 2.30pm next Wednesday at the Radisson Plaza Hotel in O'Connell Street Sydney.
Protein-based therapy helps the body remove harmful cells
Scientists have created a protein-based therapeutic tool that could change the way we treat...
Diabetes changes the structure of our hearts, study finds
Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...
Beta blockers could halt triple negative breast cancer
Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...
